These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 20417187

  • 1. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
    Kerr BD, Flatt PR, Gault VA.
    Biochem Pharmacol; 2010 Aug 01; 80(3):396-401. PubMed ID: 20417187
    [Abstract] [Full Text] [Related]

  • 2. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA, Kerr BD, Harriott P, Flatt PR.
    Clin Sci (Lond); 2011 Aug 01; 121(3):107-17. PubMed ID: 21332446
    [Abstract] [Full Text] [Related]

  • 3. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK.
    Drug Metab Dispos; 2010 Nov 01; 38(11):1944-53. PubMed ID: 20709939
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 5. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C, Huan Y, Shen N, Ji L, Sun S, Liu S, Liu Q, Gao L, Tan F, Wang Y, Shen Z.
    Biochem Biophys Res Commun; 2010 Oct 01; 400(4):563-8. PubMed ID: 20804731
    [Abstract] [Full Text] [Related]

  • 6. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA.
    Diabetes Obes Metab; 2010 Oct 01; 12(10):891-9. PubMed ID: 20920042
    [Abstract] [Full Text] [Related]

  • 7. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
    Porter WD, Flatt PR, Hölscher C, Gault VA.
    Int J Obes (Lond); 2013 May 01; 37(5):678-84. PubMed ID: 22665137
    [Abstract] [Full Text] [Related]

  • 8. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 9. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
    Lennox R, Porter DW, Flatt PR, Gault VA.
    ChemMedChem; 2013 Apr 25; 8(4):595-602. PubMed ID: 23138973
    [Abstract] [Full Text] [Related]

  • 10. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Apr 25; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 11. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 25; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 25; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 13. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 25; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 14. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM, Pathak N, Flatt YE, Gault VA, O'Harte FP, Irwin N, Flatt PR.
    Eur J Pharmacol; 2014 Nov 15; 743():69-78. PubMed ID: 25246014
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD, Gault VA, O'Harte FP, Flatt PR.
    Diabetes Obes Metab; 2005 Sep 15; 7(5):595-604. PubMed ID: 16050953
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
    Oda H, Mori A, Lee P, Saeki K, Ishioka K, Arai T, Sako T.
    Res Vet Sci; 2013 Oct 15; 95(2):381-8. PubMed ID: 23632200
    [Abstract] [Full Text] [Related]

  • 17. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr 15; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X.
    Diabetologia; 1999 Nov 15; 42(11):1324-31. PubMed ID: 10550416
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B.
    Am J Manag Care; 2011 Mar 15; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [Abstract] [Full Text] [Related]

  • 20. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
    Grossman S.
    Pharmacotherapy; 2009 Dec 15; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.